What Are Toxin-Mediated Diseases?
Discussion A poison is a generic term for “a substance with an inherent property that tends to destroy life or impair health.” A toxin is more specific and is “any poison produced by an organism, characterized by antigenicity in certain animals and high molecular weight, and including the bacterial toxins that are the causative agents of tetanus, diphtheria, etc., and such plant and animal toxins as ricin and snake venom.” A toxin does not include those substances that are made synthetically produced. Venom is also a toxin that is used by animals and insects for predation or defense which can cause ...
Source: PediatricEducation.org - April 12, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

SII to start supplying 1st made-in-India pneumococcal conjugate vaccine to Centre from Wednesday
The SII has to supply 2.4 crore doses of the vaccine to the Health Ministry by December 2021. It will be sent to 37 consignees all over India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 6, 2021 Category: Pharmaceuticals Source Type: news

Dual influenza and pneumococcal vaccination cost effective
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2021 Category: Drugs & Pharmacology Source Type: news

Lawmakers: Require nursing homes to disclose vaccine data
Nursing homes have to publicly disclose their vaccination rates for flu and pneumonia, but there’s no similar mandate for COVID-19 shots (Source: ABC News: Health)
Source: ABC News: Health - March 25, 2021 Category: Consumer Health News Tags: Health Source Type: news

CT results in COVID-19 patients predict abnormal brain MRI findings
CT images of severe COVID-19 may help clinicians predict patients' vulnerabilit...Read more on AuntMinnie.comRelated Reading: Adenopathy may occur after COVID-19 vaccination Consider COVID-19 chest imaging patterns to prep for next pandemic Heart disease rare in pro athletes after COVID-19 CT plus deep learning distinguishes COVID-19 from other pneumonia Can AI predict COVID-19 hot spots from chest CT reports? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2021 Category: Radiology Source Type: news

CT plus deep learning distinguishes COVID-19 from other pneumonia
A deep-learning algorithm improves CT's capability for distinguishing betwee...Read more on AuntMinnie.comRelated Reading: Can AI predict COVID-19 hot spots from chest CT reports? COVID-19 vaccine affects imaging results, researchers warn AI can predict need for steroid treatments in COVID-19 patients CT quantifies COVID-19 severity, ongoing conditions COVID-19, AI, and dose reduction top RSNA's CT agenda (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 3, 2021 Category: Radiology Source Type: news

Pneumococcal polysaccharide vaccine prevents ACS events in elderly, saves cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

COVID-19 Vaccination information for health care professionals, BTS
This document provides information for respiratory health care professionals in relation to the current COVID-19 vaccination programme and covers issues that may arise in discussion with patients. This might include questions around safety or immune responses from patients with chronic respiratory disease, or on immunosuppression for lung conditions as well as more general questions around vaccines/immunisation programme, including Influenza, and pneumococcal vaccines. We also highlight the role of respiratory healthcare professionals as advocates for vaccination. A significant constituency of patients may be fearful or ...
Source: Current Awareness Service for Health (CASH) - February 4, 2021 Category: Consumer Health News Source Type: news

What Are the Side Effects of the Pneumonia Vaccine?
Title: What Are the Side Effects of the Pneumonia Vaccine?Category: Diseases and ConditionsCreated: 2/4/2021 12:00:00 AMLast Editorial Review: 2/4/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - February 4, 2021 Category: Respiratory Medicine Source Type: news

Why Captain Sir Tom Moore did not take the vaccine: Family forced to speak out to clarify
CAPTAIN SIR TOM MOORE became a symbol of pride and courage in the face of the UK's darkest chapter in recent memory. Sir Tom, who raised more than £32m for the NHS, died after contracting pneumonia and testing positive for coronavirus. Did Sir Tom get vaccinated before his death? (Source: Daily Express - Health)
Source: Daily Express - Health - February 2, 2021 Category: Consumer Health News Source Type: news

Pneumococcal vaccination in adults with diabetes: modest effect on costs of pneumococcal disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, wit...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe CO...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Crohn Disease, Comorbidities Up Risk for Severe Pneumococcal Disease
Receipt of PCV13 alone or in combination with PPSV23 predicts fivefold reduced risk for SPD compared with no vaccination (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 29, 2021 Category: Respiratory Medicine Tags: Family Medicine, Gastroenterology, Infections, Internal Medicine, Pharmacy, Pulmonology, Journal, Source Type: news

Crohn Disease, Comorbidities Up Risk for Severe Pneumococcal Disease
THURSDAY, Jan. 28, 2021 -- For veterans with inflammatory bowel disease (IBD), the risk for severe pneumococcal disease (SPD) is increased with Crohn disease and with more comorbidities, and pneumococcal vaccination is associated with a reduced risk... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 28, 2021 Category: Pharmaceuticals Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Fewer Children Died in 2020, Despite the Pandemic. Experts Are Trying to Figure Out Why
Since the global pandemic began, one of the grimmer features of daily life has been watching the coronavirus death count tick up and up as the months have gone by. With so much unnecessary death in 2020, it’s surprising that in many countries, at least according to preliminary numbers, there was one significant group that actually saw its death rates fall: children. Data from the Human Mortality Database, a research project run by a global team of demographers, suggest that COVID-19 did not reverse years-long declines in child mortality, despite a mortality surge in the general population. Demographers, pediatricians...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized COVID-19 Source Type: news

Laws Promoting Flu Shot for Hospital Workers Can Cut Deaths
FRIDAY, Jan. 8, 2021 -- State laws promoting hospital worker vaccination against influenza may be effective for reducing monthly pneumonia and influenza mortality rates, especially among the elderly, according to a study published online Jan. 5 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2021 Category: Pharmaceuticals Source Type: news

If Covid-19 is Primarily a ‘First World’ Virus, Why is the Global South in Lockdown?
A lockdown closer home. Secretary-General Antonio Guterres walking the empty corridors of the UN Secretariat building in New York in 2020. Credit: United NationsBy Darini Rajasingham-SenanayakeCOLOMBO, Sri Lanka, Jan 7 2021 (IPS) The currently available Covid-19 vaccines have been authorized for ‘emergency use ‘in Europe and North America. This is due to an apparent spike in Covid-19 flu cases in the northern hemisphere as winter advances. Highly advertised vaccines are being produced and rolled out at ‘warped speed’ by powerful pharmaceutical and bio-technology companies headquartered in Euro-Ameri...
Source: IPS Inter Press Service - Health - January 7, 2021 Category: International Medicine & Public Health Authors: Darini Rajasingham-Senanayake Tags: Aid Development & Aid Editors' Choice Featured Global Headlines Health Human Rights IPS UN: Inside the Glasshouse Population Poverty & SDGs TerraViva United Nations Source Type: news

World prepares for muted New Year's Eve under Covid shadow
Britons urged to stay home; France puts 100,000 police out on patrol; Merkel laments hardest year; Times Square closed to publicSee all our coronavirus coverageMillions of people around the world are preparing for a New Year ’s Eve like no other – with lockdowns, restrictions and curfews in place in dozens of countries in an attempt to stem the spread of Covid-19 before vaccination drives start to take effect.New Year ’s Eve marks one year since the World Health Organization first mentioned a mysterious pneumonia inChina later identified as Covid-19, which went on in 2020 to kill more than 1.79 million pe...
Source: Guardian Unlimited Science - December 31, 2020 Category: Science Authors: Guardian staff and agencies Tags: Coronavirus UK news US news France Germany Australia news Europe Infectious diseases Science World news Source Type: news

Serum Institute launches India's first fully indigenously developed pneumococcal vaccine
PNEUMOSIL has been developed through a collaboration spanning over a decade among Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates Foundation. This significant milestone is aimed at improving pneumococcal conjugate vaccine affordability and enabling sustainable access for low-and middle-income countries. (Source: The Economic Times)
Source: The Economic Times - December 29, 2020 Category: Consumer Health News Source Type: news

Don ’t Let the Pandemic Stop Your Shots
Even as older adults await the coronavirus vaccine, many are skipping the standard ones. That ’s not wise, health experts say. (Source: NYT Health)
Source: NYT Health - December 28, 2020 Category: Consumer Health News Authors: Paula Span Tags: your-feed-science Whooping Cough Shingles (Disease) Diphtheria Coronavirus (2019-nCoV) Influenza Elderly Epidemics Drugs (Pharmaceuticals) Pneumonia your-feed-healthcare Vaccination and Immunization Hepatitis Tetanus Minorities Source Type: news

Vardhan launches India's first indigenously developed pneumococcal vaccine 'Pneumosil'
During clinical trials, Pneumosil was found to be safe and effective in the prevention of pneumonia and based on which Pneumosil has been licensed by the Drugs Controller General of India in July 2020 after approval from subject expert committee (SEC), he said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 28, 2020 Category: Pharmaceuticals Source Type: news

Serum Institute develops first indigenous vaccine against pneumonia; to be launched next week
India's drug regulator in July had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by the Pune-based firm. (Source: The Economic Times)
Source: The Economic Times - December 24, 2020 Category: Consumer Health News Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS Patient Care - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS Administration and Leadership - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS Latest News - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS: Journal of Emergency Medical Services News - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS Operations - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

U.S. Deaths in 2020 Top Three Million
By MIKE STOBBE AP Medical Writer NEW YORK (AP) — This is the deadliest year in U.S. history, with deaths expected to top 3 million for the first time — due mainly to the coronavirus pandemic. Final mortality data for this year will not be available for months. But preliminary numbers suggest that the United States is on track to see more than 3.2 million deaths this year, or at least 400,000 more than in 2019. U.S. deaths increase most years, so some annual rise in fatalities is expected. But the 2020 numbers amount to a jump of about 15%, and could go higher once all the deaths from this month are cou...
Source: JEMS Special Topics - December 22, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: AP News Coronavirus EMS Hospital Prehospital Source Type: news

Intellectual Property Monopolies Block Vaccine Access
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Dec 15 2020 (IPS) Just before the World Health Assembly (WHA), an 18 May open letter by world leaders and experts urged governments to ensure that all COVID-19 vaccines, treatments and tests are patent-free, fairly distributed and available to all, free of charge. Pious promises Leaders of Italy, France, Germany, Norway and the European Commission called for the vaccine to be “produced by the world, for the whole world” as a “global public good of the 21st century”, while China’s President Xi promised a vaccine developed by Chi...
Source: IPS Inter Press Service - Health - December 15, 2020 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Civil Society Development & Aid Economy & Trade Featured Global Headlines Health Human Rights Humanitarian Emergencies Poverty & SDGs TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

The great project: how Covid changed science for ever
The emergence of a novel coronavirus prompted a wave of global collaboration that has led to vaccines, treatments and the promise of new discoveriesShow your support for rigorous, independent Guardian journalismCoronavirus – latest updatesSee all our coronavirus coverageFor scientists, 5 January was a turning point in the fight against the coronavirus. That day, a team led by Prof Yong-Zhen Zhang at Fudan University in Shanghai sequenced the genetic code of the virus behind Wuhan ’s month-long pneumonia outbreak. The process took about 40 hours. Having analysed the code, Zhang reported back to the Ministry of H...
Source: Guardian Unlimited Science - December 15, 2020 Category: Science Authors: Ian Sample Tags: Coronavirus Vaccines and immunisation Infectious diseases Medical research Microbiology Health Science Society World news Source Type: news

Cells to Society: Year of the Nurse / Global Impact
This article provides a theoretical clarification of the concept "social cohesion" as it relates to health behaviors and outcomes, uncovering the critical attributes, antecedents, and consequences of social cohesion and reflecting on its future in health literature.     Read more   View More Research ...
Source: Johns Hopkins University and Health Systems Archive - December 11, 2020 Category: Nursing Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Dr. Mallika Marshall On 2nd COVID Surge: ‘ Do Not Let Your Guard Down Now ’
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"4930940","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 3, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthwatch Seen On WBZ-TV Syndicated Local Coronavirus Dr. Mallika Marshall Source Type: news

Can Some Vaccines Reduce Your Alzheimer ’s Risk?
Could vaccines play a role in preventing Alzheimer’s disease? Researchers are looking at that question more broadly after finding that the flu and pneumonia vaccines might also help protect against the devastating memory loss of Alzheimer's disease. (Source: WebMD Health)
Source: WebMD Health - December 3, 2020 Category: Consumer Health News Source Type: news

US Presidential Election Part 3: President Trump ’s Legacy of Mismanagement of the Pandemic
Credit: Whitehouse.GovBy Farhang JahanpourOXFORD, Dec 1 2020 (IPS) Covid-19 is on track to be the deadliest and one of the most catastrophic epidemics since the 1918-1919 flu pandemic, which infected about 500 million people or one-third of the world’s population at the time. The number of deaths was estimated somewhere between 17 and 50 million, and possibly as high as 100 million worldwide. The first observations of illness and mortality were documented in December 1917 at Camp Greene, North Carolina. To maintain morale, World War I censors minimized reports of casualties, but as newspapers in neutral Spain were f...
Source: IPS Inter Press Service - Health - December 1, 2020 Category: International Medicine & Public Health Authors: Farhang Jahanpour Tags: Democracy Global Geopolitics Headlines Health North America TerraViva United Nations Source Type: news

On World AIDS Day, Those Who Fought the 1980s Epidemic Find Striking Differences and Tragic Parallels in COVID-19
More than three decades after the World Health Organization (WHO) launched the first World AIDS Day on Dec. 1, 1988, the world’s leading global health organization faces another public health crisis in COVID-19. On this World AIDS Day, those who raised awareness of HIV, the virus that causes AIDS, find devastating similarities and haunting differences in America’s response to both crises. In 1981, scientists recorded the first cases of a rare pneumonia, usually found among immunosuppressed patients, among a group of gay men in Los Angeles, and noticed more cases appearing among gay men in San Francisco and New ...
Source: TIME: Health - December 1, 2020 Category: Consumer Health News Authors: Olivia B. Waxman Tags: Uncategorized COVID-19 feature HIV/AIDS Source Type: news

Fiji's vaccine program reduces childhood death and illness: study
(University of Melbourne) Fiji's national vaccine program against pneumonia, a serious lung condition, and rotavirus, a common disease which causes severe diarrhoea and vomiting, has reduced illness and death, new research shows. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 25, 2020 Category: Infectious Diseases Source Type: news

Moderna ’s COVID-19 Vaccine Is 94.5% Effective. Here’s What That Really Means
It’s wasn’t a typical Sunday morning for Dr. Stephen Hoge, president of the biotech company Moderna, and Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. They were at their respective homes in Massachusetts and Washington, D.C., waiting to to be let into a Zoom call to hear the results of the very first COVID-19 vaccine that was tested in people. The hosts were members of the independent Data Safety Monitoring Board (DSMB) that is reviewing data involving all the COVID-19 vaccine candidates supported by the U.S. government’s Operation Warp Speed program, and Hoge a...
Source: TIME: Health - November 17, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

It's not just the vaccine. There are many causes for hope in the fight against Covid | Devi Sridhar
Scientists now have better tests and treatments, and are forging a clear pathway out of this global ordealOn 5 January 2020, the World Health Organization sent amemo to governments across the world reporting a small cluster of pneumonia-like cases in Wuhan, China. For many countries, the warning was like looking through a fog. Each month, the WHO picks up on average3000 potential disease signals and chooses 30 to investigate. In early January, global health scientists like myself were trying to assess the outbreak of“Wuhan pneumonia”, as it was then called, with huge gaps in our knowledge and considerable uncer...
Source: Guardian Unlimited Science - November 16, 2020 Category: Science Authors: Devi Sridhar Tags: Coronavirus Infectious diseases Science Medical research World news UK news Source Type: news

Covid update: OCD medication shown to improve symptoms of coronavirus
COVID-19 can ravage the body, causing breathlessness, pneumonia and the need for oxygen ventilators. With the vaccine still needing to jump through protocol hoops, researchers have been looking elsewhere. (Source: Daily Express - Health)
Source: Daily Express - Health - November 13, 2020 Category: Consumer Health News Source Type: news

Pfizer and BioNTech could make $13bn from coronavirus vaccine
Johnson& Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basisCoronavirus – latest updatesSee all our coronavirus coverageThe US drugmaker Pfizer and the German biotech firm BioNTech stand to bring in nearly $13bn ( £9.8bn) in global sales from theircoronavirus vaccine next year, which will be evenly split between the two companies, according to analysts at the US investment bank Morgan Stanley.Pfizer ’s half would be more than the US pharmaceutical group’s bestselling product, a pneumonia vaccine that generated $5.8bn last year.Continue reading... (Source: G...
Source: Guardian Unlimited Science - November 10, 2020 Category: Science Authors: Julia Kollewe Tags: Pfizer Pharmaceuticals industry Coronavirus Vaccines and immunisation Business World news Infectious diseases Science Source Type: news

Directed enhanced service specification for flu updated
An updated directed enhanced service specification (DES) for the seasonal flu and pneumococcal vaccination programme 2020/21 has been published. (Source: NHS Networks)
Source: NHS Networks - November 9, 2020 Category: UK Health Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

GSK to Launch Late-Stage Testing of RSV Vaccine GSK to Launch Late-Stage Testing of RSV Vaccine
GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 22, 2020 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news

The atomic makeup of M. pneumoniae's 'nap' structure glides into view
(Osaka City University) Using X-ray crystallography and cryo-electron microscopy, an international team of scientists unravel the atomic structure of the proteins P1 and P40/P90 which make up the " Nap " structure - a protein complex that the bacterium M. pneumoniae uses to attach and move around human cells to cause pneumonia. This will allow us to better understand the " Nap " structure and develop medicine and vaccines that stop the bacterium from infecting humans. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 14, 2020 Category: Infectious Diseases Source Type: news